Success Metrics

Clinical Success Rate
79.1%

Based on 87 completed trials

Completion Rate
79%(87/110)
Active Trials
34(20%)
Results Posted
78%(68 trials)
Terminated
23(14%)

Phase Distribution

Ph not_applicable
1
1%
Ph phase_2
108
65%
Ph phase_4
1
1%
Ph phase_3
22
13%
Ph phase_1
32
19%
Ph early_phase_1
1
1%

Phase Distribution

33

Early Stage

108

Mid Stage

23

Late Stage

Phase Distribution165 total trials
Early Phase 1First-in-human
1(0.6%)
Phase 1Safety & dosage
32(19.4%)
Phase 2Efficacy & side effects
108(65.5%)
Phase 3Large-scale testing
22(13.3%)
Phase 4Post-market surveillance
1(0.6%)
N/ANon-phased studies
1(0.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

87 of 116 finished

Non-Completion Rate

25.0%

29 ended early

Currently Active

34

trials recruiting

Total Trials

167

all time

Status Distribution
Active(37)
Completed(87)
Terminated(29)
Other(14)

Detailed Status

Completed87
Terminated23
Recruiting21
Active, not recruiting13
unknown13
Withdrawn6

Development Timeline

Analytics

Development Status

Total Trials
167
Active
34
Success Rate
79.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.6%)
Phase 132 (19.4%)
Phase 2108 (65.5%)
Phase 322 (13.3%)
Phase 41 (0.6%)
N/A1 (0.6%)

Trials by Status

withdrawn64%
not_yet_recruiting32%
active_not_recruiting138%
recruiting2113%
completed8752%
suspended11%
terminated2314%
unknown138%

Recent Activity

Clinical Trials (167)

Showing 20 of 167 trialsScroll for more
NCT05564377Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Recruiting
NCT06252649Phase 3

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Recruiting
NCT07094113Phase 1

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Recruiting
NCT07659795Phase 2

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

Recruiting
NCT07172919Phase 2

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Recruiting
NCT05863195Phase 3

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Recruiting
NCT05198934Phase 3

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Completed
NCT03087071Phase 2

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

Active Not Recruiting
NCT06820463Phase 2

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Recruiting
NCT03510208Phase 1

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Recruiting
NCT05786924Phase 1

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Recruiting
NCT07318389Early Phase 1

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Not Yet Recruiting
NCT04587128Phase 2

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Active Not Recruiting
NCT06998940Phase 3

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Recruiting
NCT04787341Phase 2

PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence

Active Not Recruiting
NCT07094204Phase 1

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Recruiting
NCT05638295Phase 2

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Active Not Recruiting
NCT05694936Phase 2

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Active Not Recruiting
NCT05747625Phase 1

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Recruiting
NCT02876107Phase 2

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Active Not Recruiting

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
167